Osimertinib Combined with Chemotherapy Demonstrates Significant Overall Survival Benefit in Advanced EGFR-Mutated Lung Cancer

The combination of osimertinib with chemotherapy (pemetrexed plus either cisplatin or carboplatin) demonstrated a significant overall survival (OS) benefit in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), according to final results from the Phase 3 FLAURA2 study released by AstraZeneca in July 2025.

The data show that the combination reduced the risk of death by 20% compared to osimertinib monotherapy, with a median OS of 44.3 months versus 37.8 months (HR=0.80; 95% CI: 0.64–1.00; p=0.024). This is the first study to demonstrate an OS benefit using a third-generation tyrosine kinase inhibitor (TKI)-based combination approach.

Key study highlights include:

• The OS benefit was consistent across subgroups, including patients with brain metastases;
• Median progression-free survival (PFS) was previously reported as 25.5 months for the combination arm, compared to 16.7 months with monotherapy;
• The safety profile was manageable and consistent with the known profiles of both osimertinib and the chemotherapy agents used.

These findings support the use of osimertinib in combination with chemotherapy as an effective therapeutic strategy for patients with advanced EGFR-mutated NSCLC, contributing to meaningful advances in disease management.